Allergy Therapeutics PLC has announced the appointment of David Ball as an independent Non-Executive Director, effective immediately. David will also serve as the Chair of the Board's Audit and Risk Committee. With over 25 years of experience in financial markets, including 15 years as an equity portfolio manager and partner with Tudor Investment Corporation, David brings a wealth of executive and financial markets experience to the company.

Peter Jensen, Chairman of Allergy Therapeutics, expressed his delight at David's appointment, highlighting David's impressive breadth of experience and the positive timing for the company. David Ball also expressed his enthusiasm, stating that he looks forward to contributing to the company's leading position in the sector.

David William Dawson Ball, aged 55, is a director of Argonaute RNA Limited and was previously a director of Brainomix Limited. The company confirmed that there is no other information in relation to David Ball's appointment that is required to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information, interested parties can contact Allergy Therapeutics directly.